Spots Global Cancer Trial Database for Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Official Title: Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study

Study ID: NCT00182052

Conditions

Adenocarcinoma of the Prostate

Prostate Cancer

Interventions

Rosiglitazone

Placebo

Study Description

Brief Summary: The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.

Detailed Description: * Patients will be randomly assigned to initial treatment with either rosiglitazone or placebo orally twice daily, every day as long as there is no disease progression or serious side effects. Patients will be asked to complete a drug log to keep track of the medication. * Before treatment begins the following tests will be performed: physical exam; bone scan; blood work (including PSA level test) and a urine sample. * While on this study the following tests and procedures will be done once a month: review of side effects and routine blood tests (including PSA levels). * While on this study the following tests and procedures will be done on months 2 and 4: review of side effects; routine blood tests (including PSA levels) and urine tests. * If the patient's disease progressed the treatment code will be broken and if the patient was on placebo, they will have the option to begin taking rosiglitazone.